Cancer Letters

Cancer Letters

Volume 407, 28 October 2017, Pages 32-44
Cancer Letters

Original Article
A miR-135b-TAZ positive feedback loop promotes epithelial–mesenchymal transition (EMT) and tumorigenesis in osteosarcoma

https://doi.org/10.1016/j.canlet.2017.08.005Get rights and content

Highlights

  • TAZ is upregulated in osteosarcoma and modulates epithelial–mesenchymal transition.

  • TAZ induces miR-135b, which functions downstream of TAZ in Hippo signaling.

  • MiR-135b suppresses expression of the TAZ inhibitors LATS2, APC, and GSK-3β.

  • A miR-135b–TAZ positive feedback loop promotes tumorigenesis in osteosarcoma.

Abstract

Transcriptional co-activator with PDZ-binding motif (TAZ) is a WW domain-containing protein that regulates mesenchymal differentiation and organ development. It is also a downstream effector of the Hippo signaling pathway, which has been implicated in epithelial–mesenchymal transition (EMT) and tumorigenesis. However, the molecular mechanisms underlying TAZ function in these processes in the context of osteosarcoma (OS) are not well understood. We addressed this in the present study using U2OS and HOS cell lines. We found that TAZ signaling is maintained via a previously undescribed micro (mi)RNA-dependent positive feedback loop. The miRNA miR-135b, which is directly induced by TAZ, suppressed the TAZ inhibitors large tumor suppressor 2, adenomatous polyposis coli, and glycogen synthase kinase 3β, thereby amplifying TAZ signaling and inducing EMT. Overexpression of miR-135b caused constitutive activation of TAZ, which rescued the inhibition of cell proliferation and EMT induced by TAZ knockdown. These results provide evidence that TAZ and miR-135b engage in a positive feedback loop to regulate EMT and metastasis in OS, and suggest that both factors can be therapeutic targets for OS treatment.

Introduction

Osteosarcoma (OS) is the most common type of primary malignant bone tumor that mainly occurs in children and adolescents and has a high rate of local invasion and metastasis [1]. Chemotherapy and surgical intervention can increase the 5-year survival rate to 60%–70% [2]; however, the rate is only 30% in patients with a metastatic tumor [3], [4]. It is therefore important to clarify the molecular mechanisms underlying OS metastasis and identify new therapeutic targets in order to improve patient prognosis.

Recently, a newly discovered and evolutionarily and functionally conserved signaling pathway, Hippo pathway, has been shown to play a critical role in controlling organ size by regulating both cell proliferation and apoptosis [5]. The core Hippo signaling complex in mammals is composed of two kinases, Mst1/2 (mammalian sterile twenty-like) and Lats1/2 (large tumor suppressor). Mst1/2 forms a complex with the adaptor protein Sav1 to phosphorylate and activate Lats1/2. The activated Lats1/2, in association with the tumor suppressor Mob1, then phosphorylates and inhibits transcriptional coactivators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) [6]. TAZ and YAP do not directly bind to DNA but can be recruited to their target promoters through binding to the TEA domain (TEAD/TEF) transcription factors [7]. In mammals, there are four highly conserved TEAD/TEF transcription factors (TEAD1, TEAD2, TEAD3, TEAD4). These proteins share in common the TEA DNA binding domain, and are referred to as the TEAD proteins, and require transcriptional coactivators for transcription activation. Three broad groups of candidates for these coactivators have been identified and classified including YAP1, TAZ, vgll proteins, and p160 family of nuclear receptor coactivators [8]. With the help of coactivators, the TEAD family plays a crucial role in some physiological processes as well as in human cancers.

Tumor metastasis begins with epithelial–mesenchymal transition (EMT), a process in which epithelial cells assume a mesenchymal character and become migratory and invasive [9], [10], [11], [12]. Hence, inhibiting EMT by targeting the signaling pathways involved is a potential therapeutic strategy for cancer treatment [13], [14], [15]. Hyperactivation of Wnt signaling is known to contribute to EMT in human cancer [16], [17], [18], [19], [20]. The Wnt pathway is regulated by Hippo signaling [21]. Non-phosphorylated (active) forms of YAP/TAZ along with (TEAD) act coordinately or with Smad proteins or β-catenin/T cell factor to induce genes that regulate cell migration and cancer metastasis [22], [23], [24]. Upstream kinases Lats phosphorylate (inactivate) Hippo effector proteins, resulting in their cytoplasmic retention followed by proteasomal degradation by the glycogen synthase kinase (GSK3)-β complex or in sequestration of β-catenin and Smads, which blocks the activation of these transcription factors [20].

Micro (mi)RNAs regulate a variety of physiological processes as well as cancer development [25], [26]. MiRNA dysregulation has been implicated in OS progression [27]. We previously reported that YAP directly induces miR-130a, resulting in increased YAP activity [28]. In the present study, we investigated miRNA-mediated regulation of Hippo pathway components and found that miR-135b expression is induced by TAZ and in turn inhibits LATS2, adenomatous polyposis coli (APC), and GSK-3β protein expression. A TAZ-miR-135b positive feedback loop amplified upstream signals controlling cell proliferation and EMT. TAZ inactivation by miR-135b suppressed tumorigenesis. These results suggest that miR-135b inhibition is a novel therapeutic strategy for treatment of OS.

Section snippets

Ethics

All animal experiments were carried out according to relevant national and international guidelines and approved by the Stanford Institutional Animal Care and Use Committee (IACUC). All experiments strictly followed the panel's specific guidelines regarding the care, treatment and euthanasia of animals used in the study.

Clinical samples

Slices of formalin-fixed and paraffin-embedded primary osteosarcoma and chondroma tissues were obtained from biopsies in 16 and 20 patients before administration of neo-adjuvant

TAZ overexpression is associated with cell migration and a mesenchymal phenotype

We investigated the role of TAZ in OS cell migration with the Matrigel assay using the U2OS and HOS cell lines, which have high migratory capacity (Fig. 1A and B). We found that TAZ mRNA and protein levels were increased in U2OS and HOS cell sublines (Fig. 1C and D). Previous studies have demonstrated that EMT and cell migration are associated with tumor metastasis; we therefore examined TAZ and EMT marker expression in OS cells. We found that TAZ expression was negatively correlated with that

Discussion

EMT generates an aggressive tumor phenotype that leads to local metastasis via direct invasion or to distant metastasis via lymphatic and circulatory systems [31]. Tumor metastasis can presumably be inhibited by targeting factors involved in EMT [15], [32], [33]. The present study showed that EMT and tumorigenesis in OS are associated with TAZ upregulation. Moreover, we identified a novel TAZ–miR-135b positive feedback mechanism (Fig. 7F) that maintains EMT via amplification of Hippo signaling

Acknowledgements

The study was sponsored by the National Nature Science Fund of China (81601925, 81472064 and 61502129), the Zhejiang Provincial Natural Science Foundation of China (No. LQ16F020004), Medical Science and Technology Project of Zhejiang Province (2017179447). No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this study.

References (46)

  • B. Chan et al.

    The emerging roles of microRNAs in cancer metabolism

    Cancer Lett.

    (2015)
  • M.A. Huber et al.

    Molecular requirements for epithelial-mesenchymal transition during tumor progression

    Curr. Opin. Cell Biol.

    (2005)
  • M. Mimeault et al.

    Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies

    Ann. Oncol.

    (2007)
  • M. Cordenonsi et al.

    The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells

    Cell

    (2011)
  • X. Varelas et al.

    The Hippo pathway regulates Wnt/beta-catenin signaling

    Dev. Cell

    (2010)
  • Y.F. Lv et al.

    Downregulation of tumor suppressing STF cDNA 3 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by the Wnt/GSK-3beta/beta-catenin/Snail signaling pathway

    Cancer Lett.

    (2016)
  • Q. Wu et al.

    Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches

    Cancer Lett.

    (2014)
  • L. Azzolin et al.

    Role of TAZ as mediator of Wnt signaling

    Cell

    (2012)
  • L. Bashur et al.

    Cancer stem cells in osteosarcoma

    Case Orthop. J.

    (2013)
  • K. Ando et al.

    Current therapeutic strategies and novel approaches in osteosarcoma

    Cancers (Basel)

    (2013)
  • F. Martin-Belmonte et al.

    Epithelial cell polarity, stem cells and cancer

    Nat. Rev. Cancer

    (2011)
  • J.S. Bae et al.

    The Hippo signaling pathway provides novel anti-cancer drug targets

    Oncotarget

    (2017)
  • B. Zhao et al.

    The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version

    Genes Dev.

    (2010)
  • Cited by (51)

    • Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer

      2022, Journal of Bone Oncology
      Citation Excerpt :

      To that end, recent work showed that U2OS and HOS human OS cell lines cultured under a migratory ability had increased expression in TAZ and EMT-TFs, including N-cadherin, vimentin, and SNAIL[144]. This EMT-TF phenotypic induction was reversed through inhibition of TAZ[144]. Thus, YAP and TAZ might play divergent roles in OS pathogenesis and progression.

    • Unraveling the roles of miRNAs in regulating epithelial-to-mesenchymal transition (EMT) in osteosarcoma

      2021, Pharmacological Research
      Citation Excerpt :

      On the other hand, GSK-3β has also been reported to be able to suppress the expression of other EMT-related transcription factors like Snail1, and thus, the inhibition of GSK-3β during the Wnt signaling could also upregulate Snail1 expression [113]. The dysregulation of GSK-3β has been demonstrated to enhance EMT development in the osteosarcoma cells in both in vitro and in vivo conditions [73]. Another cellular signaling pathway that plays a vital role in EMT development in human cancer like osteosarcoma is the JAG/Notch signaling pathway [114,115].

    • Circular RNA circPDE4D Protects against Osteoarthritis by Binding to miR-103a-3p and Regulating FGF18

      2021, Molecular Therapy
      Citation Excerpt :

      The sections were stained with Safranin-O/Fast green (Solarbio, Beijing, China) or Alcian blue (Solarbio, Beijing, China) according to standard protocols. The immunohistochemistry and immunofluorescence procedures have been previously described.14,63 The statistical analyses were performed with SPSS v22.0 software.

    View all citing articles on Scopus
    View full text